Scor Se Stock Price and Market Data Insights

Scor SE stock price has experienced significant fluctuations over the years, with a high of €123.50 in 2018.

The company's market capitalization has also seen substantial growth, reaching €6.5 billion in 2020.

Scor SE's stock price has been influenced by various market and economic factors, including the COVID-19 pandemic.

One notable event was the company's acquisition of a majority stake in Sirius International Insurance Group in 2019, which had a positive impact on its stock price.

The share performance of SCOR SE stock price has been quite volatile over the past few months. The current share price is €25.24, which is a 7.50% increase from the previous month and a 27.28% increase from the past three months.

The 52-week high for SCOR SE stock is €32.48, while the 52-week low is €16.91. This indicates a significant fluctuation in the stock's price over the past year. The beta of the stock is 1.21, which means it is more volatile than the average stock.

The one-year change in the stock's price is -8.45%, which is a decline from the previous year. In contrast, the three-year and five-year changes are -15.87% and -34.08%, respectively. This suggests that the stock's performance has been declining over the long term. The change since the IPO is -87.12%, indicating a significant decline in the stock's value since its initial public offering.

Here's a summary of the stock's performance over the past year:

The stock's performance has been affected by various market and economic factors, leading to significant fluctuations in its price.

The current share price of SCOR stock is €25.24, which is a 7.50% increase from its price one month ago.

According to the 52-week high and low, SCOR stock has reached a high of €32.48 and a low of €16.91.

Here's a quick summary of SCOR's price history and performance:

The current share price of SCR is €25.24.

This price is based on the last available data, which is from January 2025.

SCR's 52-week high is €32.48, while its 52-week low is €16.91.

The beta of SCR is 1.21, indicating a relatively high level of volatility.

In the last month, the share price has increased by 7.50%.

Here's a summary of the 1-month, 3-month, and 1-year changes in SCR's share price:

Estimates in USD can be a crucial aspect of stock information. The average earnings estimate for 2025 is $0.130 USD, according to the latest data available.

The number of analysts providing estimates for 2025 has fluctuated, with 4 analysts providing estimates for the previous quarter, 1 analyst for the current quarter, and 15 analysts for the current year. This can give you an idea of the level of confidence and consensus among analysts.

The average earnings estimate for 2026 is $0.480 USD, based on data from 14 analysts. This represents a significant increase from the average estimate for 2025.

Check this out: Current Pe Ratio of Market

Here is a table summarizing the average earnings estimates for 2025 and 2026:

The average revenue estimate for 2026 is $19,915 USD, based on data from 7 analysts. This represents a significant increase from the average estimate for 2025.

The number of analysts providing revenue estimates for 2026 has decreased to 7, from 9 in the previous quarter. This could indicate a decrease in confidence among analysts, or a lack of recent data.

The average revenue estimate for 2025 is $18,806 USD, based on data from 9 analysts. This represents a significant increase from the average estimate for the previous year.

Check this out: Average Price

Sor stock price is a complex topic, but let's break it down. SCR provides life and non-life reinsurance products in several regions, including Europe, the Middle East, Africa, the Americas, Latin America, and Asia Pacific.

Their business scope is quite broad, covering a wide range of geographical areas.

SCR's fundamental analysis shows a mixed picture. In terms of valuation, they're trading at 74.3% below their estimated fair value.

Here's a breakdown of their fundamental analysis scores:

SCR's fundamental analysis suggests they have room for improvement in some areas, but their valuation and financial health scores are relatively strong.